31 results about "Lacrimal gland" patented technology

A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate [UTP], dinucleotides, cytidine 5′-triphosphate [CTP], adenosine 5′-triphosphate [ATP], or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.

Described here are devices, systems, and methods for increasing tear production by stimulating the cornea, conjunctiva, and / or subconjunctiva. In some variations, the devices may be in the form of a contact lens. The contact lens may comprise a lens body and a stimulator chip, where the stimulator chip is embedded in the lens body. An external power source wirelessly transmits energy to the stimulator chip, where the stimulator chip may convert the energy to an electric waveform to stimulate the cornea, conjunctiva, and / or subconjunctiva. Stimulation may activate the lacrimal reflex to increase tear production. The devices and systems for increasing tear production may be used in methods of treating dry eye, reducing the symptoms of tired eye, increasing comfort for contact lens wearers, and extending the number of years a contact lens user can wear contacts. Also described are methods of manufacturing a contact lens.

The present invention provides an opthalmologic apparatus that can noninvasively measure the state of the lacrimal layer formed on the cornea surface and that can quantitatively measure the state of the lacrimal layer without utilizing a reflection image from the retina.The opthalmologic apparatus according to the present invention comprises an optical projection system for projecting light of a specified pattern onto a cornea surface, and an imaging device for photographing a reflection image of the projected light from the cornea surface. An operating unit calculates the degree of distortion of the reflection image on the basis of the density value distribution of the image photographed by the imaging device. The operating unit can determine the state of the lacrimal layer using the calculated degree of distortion.

Lacrimal implants for treating diseases or disorders are disclosed. More particularly, lacrimal implants, methods of making such implants, and methods of treating ocular, respiration, inner ear or other diseases or disorders using such implants are disclosed.

The invention discloses herbal shampoo and bath foam for an infant. The herbal shampoo and bath foam is prepared from components in percentage by weight as follows: 0.6%-26% of plant extracts, 1%-10% of decyl glucoside, 1%-10% of cocamidopropyl betaine, 1%-15% of sodium cocoamphoacetate, 0.1%-5% of sodium lauroyl glutamate, 0.1%-1% of methyl glucose dioleate, 0.4%-1% of 3-[2-(ethylhexyl)oxyl]-1,2-propandiol, 0.4%-1% of phenoxyethanol, 0.01%-0.5% of EDTA-2Na, 0.1%-1% of erythritol and the balance of water, wherein the plant extracts comprise a sophora flavescens root extract, a honeysuckle flower extract, a Chrysanthellum indicum extract, wild chrysanthemum extract, a rheum palmatum root extract and a tea extract. Meanwhile, the invention discloses a preparation method of the herbal shampoo and bath foam for the infant. The herbal shampoo and bath foam prepared with the method for the infants can clean and moisturize skin and hair of the infant simultaneously without irritating lacrimal gland and skin of the infant, and has the effects of soothing and moisturizing the skin of the infant and protecting sebum of the skin.

A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate (UTP), dinucleotides, cytidine 5′-triphosphate (CTP), adenosine 5′-triphosphate (ATP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.

A biomaterial mass is inserted through a punctum into a canaliculus in the lacrimal outflow system with a syringe. The mass has an outer cross section that is less than the inner cross section of the canaliculus. The mass absorbs liquid to swell to form a lacrimal filler or sealing mechanism. The lacrimal filler has an external cross section that conforms to the internal cross section of the canaliculus and a soft outer surface relative to the surrounding tissues to prevent erosion of the canaliculus lining. The lacrimal filler forms an occlusion that prevents the outflow of liquid through the lacrimal outflow system to retain tears within the eye to maintain eye lubrication and wetness. The mass and syringe are provided in kit with a rubber stopper and, optionally, a punctal dilator, an injecting catheter, and an enzyme for dissolving or degrading the lacrimal filler at a later time.

This invention is in the field of medical intervention related to the lacrimal system. The invention relates to a lacrimal system device and methods of using the device for drug delivery to the eye, sinuses and / or periocular tissues.

Disclosed herein is system for inserting lacrimal stents utilizing a rigid tapered probe and a flexible, blunt-tipped probe, wherein both probes provide a channel for directing a guidewire. The guidewire assists in efficiently positioning lacrimal stents, while minimizing possible injury to the lacrimal apparatus structures.

The invention concerns lachrymal plugs, and methods for setting said devices. It concerns a lachrymal plug (10) designed to be inserted in the lachrymal canaliculi (5), said plug, optionally provided with an axial duct, comprising on its outer walls flexible elements (11) foldable on said walls to enable the plug to be inserted in the lachrymal duct and adapted to straighten up once the lachrymal plug is set, so as to maintain the latter in position. The invention generally concerns means for controlling the flow of tears running from the surface of the eye towards the nasal cavity.

A paranasal sinus access implant device to provide an artificial fluid path in fluid communication with the lacrimal apparatus may be implanted through a fistula opening into the lacrimal apparatus. The implant device may have a conduit with a first longitudinal portion having a larger minimum wall thickness than a minimum wall thickness of a second a second longitudinal portion of the conduit located distal of the first longitudinal portion. Various kits may include a paranasal sinus access implant device and one of more other components for a procedure involving implantation. A method involves use of a cutting tool to cut away tissue to prepare a fistula sized for implantation.

The invention relates to a keratoconjunctivitis sicca preventing and treating eye drop and a preparation and application method thereof. The keratoconjunctivitis sicca preventing and treating eye drop is composed of cyoloalliin, anthocyanin, dextranum, hydroxypropyl methyl cellulose, sodium chloride, potassium chloride, sodium borate, pH regulator and purified water. During application, the keratoconjunctivitis sicca preventing and treating eye drop can supplement water for eyes, form protective films on the surfaces of eyes and reduce water evaporation to effective relieve the symptoms caused by keratoconjunctivitis sicca such as dry eyes, and meanwhile, can stimulate secretion of lacrimal glands and increase the number of times of blinking; the cyoloalliin can inhibit secretion of inflammatory factors to release the clinical symptom of dry eyes and meanwhile fundamentally cure the keratoconjunctivitis sicca; besides, the keratoconjunctivitis sicca preventing and treating eye drop is free from preservatives, safe, non-irritative to eyes, high in long-term stability and applicable to wide application of prevention and treatment of various kinds of keratoconjunctivitis sicca.

The invention provides a medicament for treating a dry eye. The medicament for treating the dry eye is prepared from the following constituents by weight: 5-10 grams of bupleurum, 10-20 grams of white paeony root, 10-15 grams of Chinese angelica, 8-15 grams of dwarf lilyturf tuber, 5-10 grams of mint, 10-15 grams of campanumaea pilosula, 10-30 grams of rehmanniae praeparatum, 5-15 grams of Chinese magnoliavine fruit and 80-100 grams of dextrin. The medicine mainly aims at a patient with the dry eye and can be taken by the patient who is diagnosed with the dry eye in an outpatient department according to following usage and dosage: twice daily, a small bag each time by dissolving with warm water and 15 days for a course of treatment. No contraindication is needed to be noticed by orally taking this medicament. The medicament has effects of soothing the liver, nourishing yin and improving eye sight, human physiological function and immunity, has a certain action of imitating androgen, and can be used for dredging a lachrymal catheter, inhibiting inflammation, restoring tear gland, facilitating tear secretion by the tear gland, enabling dry and burning sensation of the eye to disappear and basically solving the problems of eye discomfort, eye acerbity, lachrymation, light sensitivity and visual deterioration.

A lacrimal stent for intraluminal drainage of a mammal is provided having an elongated tubular member configured to be inserted into at least a portion of the lacrimal drainage structures of the mammal. The elongated tubular member includes an exterior sidewall surface and an interior lumen. The lacrimal stent further includes at least one axial port extending through the exterior sidewall surface to the lumen of the elongated tubular member. The axial port is configured to permit fluidic flow therethrough of the tears of the mammal into the lumen for the purpose of intraluminal drainage.

The invention provides an eye drop collector. The eye drop collector comprises an eye drop gun, a liquid taking device and an eye drop storage tube, wherein the interior of the eye drop gun is detachably connected with the liquid taking device, one end of the liquid taking device is detachably connected with the eye drop storage tube, and the eye drop storage tube is arranged at the tail of the eye drop gun. The eye drop collector has the advantages that eye drops of the human body can be rapidly, accurately and safely collected, the liquid taking device is fixed through the eye drop gun to ensure that a user can accurately puncture a suction needle into the lacrimal gland of the eye of the human body, and therefore the problems that the eye drops of a doctor are difficult to collect, theoperation is inconvenient, and consequently the surgical risk is increased are solved.

The invention relates to a fast shredding device. A handle is arranged on the upper end of a round metal wire net through a support frame. The fast shredding device also comprises a box body matched with the diameter of the round metal wire net, and the round metal wire net is an alloy steel wire net. The fast shredding device provided by the invention has the advantages that the vegetable shredding operation can be completed through once cutting, the shredding does not need to be completed by a kitchen knife for many times, the efficiency is improved, shredded shreds have the same size and are uniform and attractive, in addition, lacrimal gland stimulation caused by juice of spicy vegetables can be avoided during the spicy vegetable cutting, the occurrence of condition of tear bursting of people is avoided, the box body is used as a container for containing vegetables during the shredding, cleanness and sanitation are realized, simultaneously, the box body is also used as the container for the cut vegetable shreds, cleanness and sanitation are realized, and the secondary pollution caused by transferring is avoided. The hardness of the alloy steel wire net is high, the deformation prevention in multi-time cutting can be realized, and the service life is prolonged. The fast shredding device also has the advantages that the structure is simple, the use is convenient, the manufacture cost is low, and the fast shredding device is suitable for large-range popularization and application.

The invention relates to a production method of a dog food additive capable of preventing eye diseases and hepatitis. The production method includes: weighing raw materials which comprise Hedyotis diffusa, radix isatidis, herba hyperici japonici and the like capable of preventing infectious hepatitis, honeysuckle, flos chrysanthemi indici, fructus forsythia, radix glycyrrhizae, cortex eucommiae and the like, crushing and mixing the raw materials, adding water to perform heating filtration to obtain filtrate, adding dextrin, and granulating and drying to obtain the dog food additive. The production method has the advantages that the Hedyotis diffusa, the radix isatidis, the herba hyperici japonici and the like used by dog food additive have effects of clearing heat and toxic materials, protecting the liver and tonifying the middle-Jiao and qi and can enhance immunity so as to prevent dog infectious hepatitis; the honeysuckle and the flos chrysanthemi indici used by the dog food additivecan reduce tear increasing caused by lacrimal gland a d canalis nasolacrimalis abnormity and lower eye discomfort; the fructus forsythia, the radix glycyrrhizae, the cortex eucommiae and the like used by the dog food additive can enhance the disease resistance of pet dogs, improve the appetite of the pet dogs and promote the digestion of the pet dogs.

Swimming goggles include left and right frame bodies installed with lenses, a connecting element, and protective pads and head strap bases. The left and right frame bodies each has inner and outer peripheral faces. The protective pads each has a connecting portion having a connecting face and an abutting face. Lip portions are respectively formed along the inner peripheral faces of the left and right frame bodies. The connecting faces integrally encompass the lip portions. The abutting faces are inclined with respect to face portions corresponding to an area above the eye socket and adjacent to an eyebrow, a side portion of a nose bridge adjacent to lacrimal gland at an inner side portion of the eye socket, an area adjacent to an under-eye bag below the eye socket, and an outer eye corner with respect to an outer side portion of the eye socket adjacent to a temple.

The invention relates to the technical field of eye drops, in particular to lanosterol eye drops and a preparation method thereof. The eye drops comprise lanosterol compounds, vitamin A, vitamin E, a traditional Chinese medicine extract and a thickening agent. According to the eye drops, the lanosterol compound is used as a main material, the effect of preventing or assisting in treating cataract is achieved, low-dosage vitamin A and vitamin E are added, vitamin A can increase lacrimal gland secretion and has a good improvement effect on xerophthalmia, vitamin E has an anti-oxidation effect, eyes are protected from being attacked by free radicals, and the thickening agent is added to improve the emulsification dispersity, so that the wetting effect of the eye drops is ensured. In addition, the traditional Chinese medicine extracting solution extracted from various traditional Chinese medicines is added, and the eye drops have the effects of removing nebula and improving eyesight and have good prevention and treatment effects on xerophthalmia, blurred vision, cataract and the like.

The present invention pertains generally to the field of coolants and medical therapy. More particularly, the present invention relates to certain anti-nociceptive agents, such as [((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester, that are potent and long-acting and selectively cooling for non-keratinized epithelial tissues as compared to keratinized epithelial tissues, and are useful, for example, for the treatment of (e.g., the alleviation of symptoms of; the amelioration of) sensory discomfort of non-keratinized stratified epithelial (NKSE) tissue;and so for treatment of: sensory discomfort of an ocular surface, an eyelid, a margin of an eyelid, an anterior part of an eyeball, a conjunctiva, a lachrymal system, a pre-corneal film, or a cornea, a lining of the oral cavity, an internal portion of the lips, a pharyngeal surface, an esophageal surface, or an anogenital surface; eye discomfort, e.g., caused by extended wear of contact lenses, by eye strain and / or fatigue, by air pollutants, by excessive exposure to the sun, by conjunctivitis, by dry eye syndrome; sensory discomfort associated with oral mucositis; airway (e.g., larynx, trachea, and / or bronchi) tightness, discomfort in the airways (e.g., larynx, trachea, and / or bronchi), choking, cough, and / or dyspnea, e.g., associated with asthma and / or chronic obstructive pulmonary diseases (COPD).

The invention relates to a keratoconjunctivitis sicca preventing and treating eye drop and a preparation and application method thereof. The keratoconjunctivitis sicca preventing and treating eye drop is composed of cyoloalliin, anthocyanin, dextranum, hydroxypropyl methyl cellulose, sodium chloride, potassium chloride, sodium borate, pH regulator and purified water. During application, the keratoconjunctivitis sicca preventing and treating eye drop can supplement water for eyes, form protective films on the surfaces of eyes and reduce water evaporation to effective relieve the symptoms caused by keratoconjunctivitis sicca such as dry eyes, and meanwhile, can stimulate secretion of lacrimal glands and increase the number of times of blinking; the cyoloalliin can inhibit secretion of inflammatory factors to release the clinical symptom of dry eyes and meanwhile fundamentally cure the keratoconjunctivitis sicca; besides, the keratoconjunctivitis sicca preventing and treating eye drop is free from preservatives, safe, non-irritative to eyes, high in long-term stability and applicable to wide application of prevention and treatment of various kinds of keratoconjunctivitis sicca.

The present invention pertains generally to the field of coolants and medical therapy. More particularly, the present invention relates to certain anti-nociceptive agents, such as [((1R,2S,5f?)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester, that are potent and long-acting and selectively cooling for non-keratinized epithelial tissues as compared to keratinized epithelial tissues, and are useful, for example, for the treatment of (e.g., the alleviation of symptoms of; the amelioration of) sensory discomfort of non-keratinized stratified epithelial (NKSE) tissue; and so for treatment of: sensory discomfort of an ocular surface, an eyelid, a margin of an eyelid, an anterior part of an eyeball, a conjunctiva, a lachrymal system, a pre-corneal film, or a cornea, a lining of the oral cavity, an internal portion of the lips, a pharyngeal surface, an esophageal surface, or an anogenital surface; eye discomfort, e.g., caused by extended wear of contact lenses, by eye strain and / or fatigue, by air pollutants, by excessive exposure to the sun, by conjunctivitis, by dry eye syndrome; sensory discomfort associated with oral mucositis; airway (e.g., larynx, trachea, and / or bronchi) tightness, discomfort in the airways (e.g., larynx, trachea, and / or bronchi), choking, cough, and / or dyspnea, e.g., associated with asthma and / or chronic obstructive pulmonary diseases (COPD).

The invention provides a nasal cavity dacryocyst drainage support frame, which comprises a drainage body, wherein a drainage cavity is formed inside the drainage body, a drainage disc used for being in contact with the lachrymal gland is arranged at the upper part of the drainage body, the upper surface of the drainage disc is a plane, a plurality of drainage holes communicated with the drainage cavity are formed in the drainage disc, the lower part of the drainage body is connected with a drainage branch tube, and the drainage branch tube is connected with the drainage cavity. The nasal cavity dacryocyst drainage support frame has the advantages that the drainage disc is in contact with the lachrymal gland of the human body, the contact area is increased, the tears can be conveniently sucked, the liquid can be discharged out through the drainage branch tube after entering the drainage cavity through the drainage holes, the airflow in a drainage passage is smooth, and the drainage effect is good.

The invention discloses the application of ganoderma acid A and its derivatives or ganoderma total triterpenes in the preparation of medicines for treating eye diseases. Drugs or functional products composed of ganoderma acid A or its derivatives or ganoderma triterpenoids can significantly reduce lacrimal gland and corneal lesions in naturally aging mice, and the body's metabolism level is closer to the youthful state, and can prevent cataracts and eye degeneration Sexual lesions and other eye diseases, the effect is clear, and the safety is high.

A device to determine a state of the lacrimal layer of the eye includes at least one light source arranged to form a pattern of source points for projecting a plurality of light rays onto a cornea surface; a lens-camera system arranged to receive a respective plurality of reflected light rays reflected on the cornea surface, thereby forming a pattern of image points; and a computational unit arranged to determine on the basis of the image points the state of the lacrimal layer of the eye and / or to determine on the basis of the image points data representative for the state of the lacrimal layer of the eye and to provide the data representative for the state of the lacrimal layer of the eye to a user.

The invention discloses a high-stability PAC1 type receptor specific agonist MPAPO and a preparation method and an application thereof. Compared with wild type PACAP, the agonist MPAPO has the following different points: the 17th changes from wild type methionine to leucine by mutation; the 27th changes from wild type leucine to lysine by mutation; the 28th changes from wild type glycin to lysineby mutation; and one methionine is added at the N end. The differences lead the MPAPO to have higher stability and specific activation activity to a PAC1 type receptor; furthermore the stability is about 30 times higher than that of the wild type PACAP. Experiments prove that the agonist MPAPO can be applied in the preparation of drugs with the following functions: promoting nerve regeneration and repair after nerve injuries, such as promoting corneal neuritogenesis after corneal injuries, promoting corneal epithelial cell repair, improving corneal sensitivity and improving the lacrimal glandsecretion function.

The invention discloses a high-stability PAC1 type receptor specific agonist MPAPO and a preparation method and an application thereof. Compared with wild type PACAP, the agonist MPAPO has the following different points: the 17th changes from wild type methionine to leucine by mutation; the 27th changes from wild type leucine to lysine by mutation; the 28th changes from wild type glycin to lysineby mutation; and one methionine is added at the N end. The differences lead the MPAPO to have higher stability and specific activation activity to a PAC1 type receptor; furthermore the stability is about 30 times higher than that of the wild type PACAP. Experiments prove that the agonist MPAPO can be applied in the preparation of drugs with the following functions: promoting nerve regeneration and repair after nerve injuries, such as promoting corneal neuritogenesis after corneal injuries, promoting corneal epithelial cell repair, improving corneal sensitivity and improving the lacrimal glandsecretion function.